This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Evotec AG

Drug Names(s): BI860585, BI-860585, BI 860585, EVT 070, EVT-070

Description: EVT070 (BI 860585) is a proprietary compound with an undisclosed mechanism of action.

Deal Structure: Evotec and Boehringer
In September 2004, Evotec announced a research collaboration with Boehringer Ingelheim. Under the terms of the collaboration, Boehringer and Evotec will jointly identify and develop pre-clinical development candidates. Boehringer Ingelheim will make research payments, additional discovery and development payments, and royalties to Evotec.

In November 2009, Evotec and Boehringer extended the research collaboration for a further 4 years. Over the term of the extension Evotec will receive research funding of around EUR 15 million plus success milestones and royalties.

In October 2014, Evotec received notice that Boehringer Ingelheim decided not to further pursue development of EVT070 for strategic reasons. This resulted in an impairment of the respective intangible asset; rights to the EVT070 project will revert back to Evotec.

EVT070 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug